Srs Capital Advisors, Inc. Mereo Biopharma Group PLC Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 4,000 shares of MREO stock, worth $16,680. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,000
Previous 4,000
-0.0%
Holding current value
$16,680
Previous $13,000
7.69%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding MREO
# of Institutions
85Shares Held
102MCall Options Held
121KPut Options Held
208K-
Rubric Capital Management LP New York, NY15.3MShares$63.8 Million1.63% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.8MShares$49.2 Million0.08% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.28MShares$38.7 Million1.04% of portfolio
-
Mangrove Partners New York, NY8.75MShares$36.5 Million3.54% of portfolio
-
Janus Henderson Group PLC London, X07.88MShares$32.9 Million0.02% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $521M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...